Advertisement

GlaxoSmithKline submits application for COPD drug in EU

GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).

GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).

The treatment, which is administered using the company's Ellipta inhaler, is designed to relive symptoms in adult suffers of COPD.

The group said a marketing authoristion application (MAA) for the treatment has been submitted to the European Medicines Agency (EMA).

Advertisement - Article continues below

Regulatory filings for the product are imminent in the US and planned in other countries during the course of 2013, it added.

The share price was down 0.36% to 1,676p by 11:00 on Friday.

NR

Advertisement
Advertisement

Recommended

Visit/investments/investment-strategy/601044/broker-safety-your-questions-answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
Visit/investments/investment-strategy/600861/how-demographics-affects-stock-valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Visit/investments/stocks-and-shares/600863/sirius-minerals-anglo-american-takeover
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Visit/investments/stockmarkets/600634/why-investors-should-be-cautiously-bullish-for-2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Visit/investments/investment-strategy/601387/how-john-maynard-keynes-learned-the-folly-of-market-timing
Investment strategy

How John Maynard Keynes learned the folly of market timing

In an extract from his book The Sceptical Investor, John Stepek explains how the great economist John Maynard Keynes came a cropper when he first star…
25 May 2020
Visit/investments/stockmarkets/emerging-markets/601362/a-new-lease-of-life-for-the-brics
Emerging markets

A new lease of life for the Brics

Emerging markets are having a surprisingly good crisis. Their long-predicted rise will now continue.
24 May 2020
Visit/investments/investment-strategy/601379/battling-volatility-the-benefits-of-an-active-manager
Sponsored

Battling volatility: The benefits of an active manager

SPONSORED CONTENT – Alastair Wilson, managing director of Close Brothers, on the advantages of active investing in times of crisis.
21 May 2020